Login




Nefrologia clinica

Rituximab in monoterapia vs micofenolato e vs boli di ciclofosfamide nel trattamento della nefrite lupica attiva (NLA).

comunicazione

Figura 1 di 20.


Figura 2 di 20.


Figura 4 di 20.

Riferimenti Bibliografici:

  1. Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, Steinberg AD, Gourley MF, Klippel JH, Balow JE, Boumpas DT. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Ann Rheum Dis 2002;46(4):995-1002. [2]
  2. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ; Collaborative Study Group Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3(1):46-53. [3] (full text)
  3. Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risck of terminal renal failure. J Rheumatol. 2006; 33:1563-1569. [4]
  4. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010 Jan;69(1):61-4. doi: 10.1136/ard.2008.102533. [5]
  5. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004 Aug;50(8):2559-68. [6] (full text)
  6. Gabriella Moroni, Silvana Quaglini, Beniamina Gallelli, Giovanni Banfi, Piergiorgio Messa And Claudio Ponticelli. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Trasplant 2007;22:2531-2539. [7] (full text)

Figura 5 di 20.


Figura 7 di 20.


Figura 9 di 20.


Figura 10 di 20.


Figura 11 di 20.


Figura 12 di 20.


Figura 13 di 20.


Figura 14 di 20.


Figura 15 di 20.


Figura 16 di 20.


Figura 17 di 20.


Figura 18 di 20.


Figura 19 di 20.


Figura 20 di 20.


BibliografiaReferences

[1] Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the rheumatic diseases 2012 Nov;71(11):1771-82 (full text)

[2] Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis and rheumatism 2002 Apr;46(4):995-1002

[3] Chen YE, Korbet SM, Katz RS et al. Value of a complete or partial remission in severe lupus nephritis. Clinical journal of the American Society of Nephrology : CJASN 2008 Jan;3(1):46-53 (full text)

[4] Faurschou M, Starklint H, Halberg P et al. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. The Journal of rheumatology 2006 Aug;33(8):1563-9

[5] Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Annals of the rheumatic diseases 2010 Jan;69(1):61-4

[6] Mok CC, Ying KY, Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis and rheumatism 2004 Aug;50(8):2559-68 (full text)

[7] Moroni G, Quaglini S, Gallelli B et al. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2007 Sep;22(9):2531-9 (full text)

[8] Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis and rheumatism 2012 Apr;64(4):1215-26 (full text)

[9] Moroni G, Gallelli B, Sinico RA et al. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. Annals of the rheumatic diseases 2012 Oct;71(10):1751-2

release  1
pubblicata il  25 settembre 2013 
da Francesca Raffiotta 1, Gabriella Moroni 1, Barbara Trezzi 2, Nicoletta Mezzina 2, Valentina Binda 1, Piergiorgio Messa 1, Renato Sinico 2
(1 Divisione di Nefrologia & Dialisi, IRCCS Fondazione Ca’ Granda, Ospedale Maggiore, Mangiagalli, Regina Elena, Milano 2 Divisone di Nefrologia e Immunologia clinica, Ospedale San Carlo Borromeo, Milano, Italy, )
Parole chiave: lupus eritematoso sistemico, rituximab
Non sono presenti commenti

Per inserire una domanda, segnalare la tua esperienza, un tuo commento o una richiesta di precisazione fai il login con il tuo nome utente e password.

Se non lo sei ancora puoi registrati partendo da qui.

WebPoster

Link utili

Realizzazione: Tesi S.p.A.

 Per assistenza contattare: Lucia Piumetto, Tesi S.p.A.
0172 476301 — lucia.piumetto@gruppotesi.com